Article Text

Download PDFPDF

437 Optimised achilles VELOSTM process 2b manufacturing platform generates a significant dose boost of reactive CD8 and CD4 clonal neoantigen-reactive T cells for the treatment of solid cancer

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.